Trial site
Clinica Universidad de Navarra Madrid
Madrid, 28027, SpainNot linked to an institution yet
- 16running trials
- 13closed trials
The trials here
What the 29 trials at this site are about, from their registry records.
- Phase
- Phase 19 trials
- Phase 1/26 trials
- Phase 26 trials
- Phase 36 trials
- Phase 2/31 trial
- Status
- Active, not recruiting8 trials
- Completed8 trials
- Recruiting5 trials
- Terminated5 trials
- Not yet recruiting3 trials
- Lead sponsor
- Hoffmann-La Roche7 trials
- Boehringer Ingelheim2 trials
- Eli Lilly and Company2 trials
- NovoCure GmbH2 trials
- BicycleTx Limited1 trial
- and 15 more
Running trials
Not yet recruiting
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
NCT07928258· Phase 1· Eli Lilly and Company· Source
Not yet recruiting
A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation
NCT07814417· Phase 2· Eli Lilly and Company· Source
Contact: Ignacio Matos Garcia (principal investigator)
Recruiting
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
NCT07701941· Phase 1/2· Daiichi Sankyo· Source
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146· Phase 3· Zai Lab (Shanghai) Co., Ltd.· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215· Phase 3· Hoffmann-La Roche· Source
Recruiting
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
NCT06216301· Phase 3· NovoCure GmbH· Source
Recruiting
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357· Phase 1/2· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
NCT05955508· Phase 2· Regeneron Pharmaceuticals· Source
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
NCT06004245· Phase 1· Vividion Therapeutics, Inc.· Source
Active, not recruiting
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
NCT06225596· Phase 2· BicycleTx Limited· Source
Active, not recruiting
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
NCT05789069· Phase 1· HiFiBiO Therapeutics· Source
Recruiting
Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
NCT05416307· Phase 2/3· Electra Therapeutics Inc.· Source
Contact: Clinical Trials
Active, not recruiting
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
NCT04988386· Phase 3· Eidos Therapeutics, a BridgeBio company· Source
Active, not recruiting
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
NCT04770896· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
NCT04140500· Phase 1/2· Hoffmann-La Roche· Source
Active, not recruiting
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT03767348· Phase 2· Replimune, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Terminated
LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT06558799· Phase 2· NovoCure GmbH· Source
Completed
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
NCT05867121· Phase 1· Genentech, Inc.· Source
Completed
A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer
NCT05846594· Hoffmann-La Roche· Source
Completed
A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers
NCT05383170· Phase 1/2· Cytovation AS· Source
Terminated
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
NCT05256381· Phase 2· SOTIO Biotech AG· Source
Completed
A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma
NCT05187624· Phase 1· Hoffmann-La Roche· Source
Completed
Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment
NCT04826003· Phase 1· Hoffmann-La Roche· Source
Terminated
A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
NCT04732286· Phase 3· Hoffmann-La Roche· Source
Terminated
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
NCT04868877· Phase 1/2· Merus B.V.· Source
Terminated
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
NCT04442126· Phase 1/2· Numab Therapeutics AG· Source
Completed
A Study of DF6002 Alone and in Combination With Nivolumab
NCT04423029· Phase 1· Dragonfly Therapeutics· Source
Completed
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
NCT03748186· Phase 1· Sutro Biopharma, Inc.· Source
Completed
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
NCT03099174· Phase 1· Boehringer Ingelheim· Source
Report an error